Release Date: 01/17/2017; Expiration Date: 01/17/2018
To take this course, click here
PROGRAM OVERVIEW
New clinical classification of MDS, as well as the evaluation of the implications of molecular mutations, have generated valuable advances for aiding management of patients with this disease. These recent findings will be discussed during this program. The unique nature of treatment-related MDS as a specific subset of MDS will be also be reviewed. Given the understanding of immunologic abnormalities in MDS, therapeutic interventions using immune checkpoint inhibitors and T-cell based therapies will add to this discussion, as will a number of the novel treatments using biologic targeted approaches for anemias and higher risk patients.
TARGET AUDIENCE
This activity is intended for physicians, oncology nurses, nurse practitioners, physician assistants, pharmacists and other health care professionals interested in the treatment and management of patients with Myelodysplastic Syndromes.
LEARNING OBJECTIVES
Upon completion of the educational activity, participants should be able to:
FACULTY
University of California, San Diego
Moores Cancer Center
La Jolla, California
Dr. Bejar has disclosed the following relevant financial relationships:
Consultant: Celgene Corporation, GENOPTIX, Foundation Medicine, Inc.
Data Safety Monitoring Board: Celgene Corporation
Massachusetts General Hospital
Harvard Medical School
Boston, Massachusetts
Discloses no financial relationships with pharmaceutical or medical product manufacturers.
University of Chicago
Chicago, Illinois
Dr. Larson has disclosed the following relevant financial relationships:
Consultant: ARIAD Pharmaceuticals, Inc., Amgen, Bristol-Myers Squibb, Celgene Corporation, Erytech Pharma, Novartis, Pfizer Inc.
Contracted Research: Astellas Pharma US, Inc., Celgene Corporation, Daiichi Sankyo, Inc., Erytech Pharma
Dr. Nimer has disclosed the following relevant financial relationships:
Consultant: BioReference, Onconova Therapeutics, Inc.
Data and Safety Monitoring Board: Celgene Corporation, Janssen Pharmaceuticals, Inc.
University Hospital Carl Gustav Carus
Dresden, Germany
Dr. Platzbecker has disclosed the following relevant financial relationships:
Consultant: Amgen, Celgene Corporation, Janssen Pharmaceuticals, Inc., Novartis
Cincinnati Children’s Hospital Medical Center
Cincinnati, Ohio
Discloses no financial relationships with pharmaceutical or medical product manufacturers.
ACCREDITATION
CME/CE Credit provided by AKH Inc., Advancing Knowledge in Healthcare
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AKH Inc., Advancing Knowledge in Healthcare and the Myelodysplastic Syndromes Foundation, Inc. (MDSF). AKH Inc., Advancing Knowledge in Healthcare is accredited by the ACCME to provide continuing medical education for physicians.
AKH Inc., Advancing Knowledge in Healthcare designates this enduring activity for a maximum of 3.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity
NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME.
AKH, Inc., Advancing Knowledge in Healthcare is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
AKH, Inc., Advancing Knowledge in Healthcare approves this knowledge- based activity for 3.5 contact hour(s) (0.35 CEUs). UAN 0077-9999-17-002-H04-P. Initial Release Date: January 17, 2017.
AKH, Inc., Advancing Knowledge in Healthcare is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.This activity is awarded 3.5 Contact Hours.
Activity is jointly-provided by AKH Inc., Advancing Knowledge in Healthcare and the Myelodysplastic Syndromes Foundation, Inc. (MDSF).
This activity is supported by an educational grant from Celgene Corporation and Onconova Therapeutics, Inc.
There is no fee to participate in this activity.
Method of Participation Statements of credit will be awarded based on the participant reviewing the entire presentation, scoring a 70% on the post test, and completing and submitting an activity evaluation. A statement of credit will be available upon completion of an online evaluation/claimed credit form. You must participate in the entire activity to receive credit. If you have questions about this CME/CE activity, please contact AKH Inc. at tbrignoni@akhcme.com. To fully understand and translate learning, AKH suggests the following methods of active learning for this activity:
For Pharmacists: Upon receipt of the completed activity evaluation form, transcript information will be available at www.mycpemonitor.net within 4 weeks
It is the policy of AKH Inc. and MDS to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are resolved by AKH and MDS prior to accreditation of the activity and may include any of or combination of the following: attestation to non-commercial content; notification of independent and certified CME/CE expectations; referral to National Faculty Initiative training; restriction of topic area or content; restriction to discussion of science only; amendment of content to eliminate discussion of device or technique; use of other faculty for discussion of recommendations; independent review against criteria ensuring evidence support recommendation; moderator review; and peer review. AKH/MDS planners and reviewers have no relevant financial relationships to disclose.
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. and MDS specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant’s misunderstanding of the content.
REQUIRED HARDWARE / SOFTWARE:
Copyright © 2017 MDS and AKH Inc. No part of this publication may be produced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical photocopying, recording, or otherwise, without the prior permission of the publisher
To take this course, click here
